Periodontal disease in a patient receiving Bevacizumab: a case report

INTRODUCTION: Bevacizumab is a monoclonal antibody that inhibits the action of vascular endothelial growth factor (VEGF) thereby acting as an angiogenesis inhibitor. As a result, supply of oxygen and nutrients to tissues is impaired and tumour cell growth is reduced. Reported side effects due to bev...

Descripción completa

Detalles Bibliográficos
Autores principales: Gujral, Dorothy M, Bhattacharyya, Sanjeev, Hargreaves, Peter, Middleton, Gary W
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2262909/
https://www.ncbi.nlm.nih.gov/pubmed/18271967
http://dx.doi.org/10.1186/1752-1947-2-47

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2262909/
https://www.ncbi.nlm.nih.gov/pubmed/18271967
http://dx.doi.org/10.1186/1752-1947-2-47

Ejemplares similares